Analyzing Heyu Biological Technology (OTCMKTS:HYBT) and QT Imaging (NASDAQ:QTI)

Profitability

This table compares QT Imaging and Heyu Biological Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QT Imaging	N/A	N/A	-65.94%
Heyu Biological Technology	-453.55%	-6.43%	-4.43%

Insider & Institutional Ownership

24.2% of QT Imaging shares are owned by institutional investors. 75.4% of QT Imaging shares are owned by insiders. Comparatively, 89.2% of Heyu Biological Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares QT Imaging and Heyu Biological Technology”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QT Imaging	$4.00 million	2.86	-$4.03 million	N/A	N/A
Heyu Biological Technology	$80,000.00	642.07	-$270,000.00	N/A	N/A

Heyu Biological Technology has lower revenue, but higher earnings than QT Imaging.

Risk and Volatility

QT Imaging has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500. Comparatively, Heyu Biological Technology has a beta of -17.74, meaning that its stock price is 1,874% less volatile than the S&P 500.

Summary

QT Imaging beats Heyu Biological Technology on 5 of the 9 factors compared between the two stocks.

About QT Imaging

QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems for detection, diagnosis, monitoring, and treatment of diseases. The company offers QT Ultrasound Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient’s breast. QT Imaging Holdings, Inc. was founded in 2011 and is based in Novato, California.

About Heyu Biological Technology

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.